UPDATE: Piper Jaffray Upgrades Pacific Biosciences of California to Neutral, Raises PT Following 2Q13 Revenue Report

In a report published Friday, Piper Jaffray analyst William R. Quirk upgraded the rating on Pacific Biosciences of California PACB from Underweight to Neutral, and raised the price target from $2.00 to $3.10. In the report, Piper Jaffray noted, “Pacific Biosciences reported 2Q13 revenue of $6.0M, in line with our $6.1M estimate. During the quarter, PacBio validated 3 RS instruments, in line with our 3 estimate and added 7 orders (PJC: 4), yielding a net backlog of ~$6.2M or 10 instruments. PacBio received 54 upgrade orders (70% of installed base, 23 in 2Q13) as of the end of the quarter. We are encouraged with another quarter of better-than-expected RS placements and with a renewed sense of stability, we believe a Neutral rating is more appropriate.” Pacific Biosciences of California closed on Thursday at $2.67.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsPiper JaffrayWilliam R. Quirk
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!